Innovative digital healthcare company BlinkLab Limited (ASX:BB1) has reached a research and clinical partnership with the INTER-PSY in the Netherlands.
As part of the agreement, INTER-PSY will run a prospective study on the ability of the BlinkLab app to aid in diagnosis of autism in children between two to six ears of age that are referred to INTER-PSY. By analysing the behavioural and physiological responses collected via the app, BlinkLab will aim to identify autism characteristics, potentially offering patients a more rapid, accessible and objective assessment method.
Through this partnership, INTER-PSY will use BlinkLab’s technology to evaluate whether the technology can enhance their diagnostic accuracy and efficiency in the clinic. This partnership between BlinkLab and INTER-PSY demonstrates the potential of an AI mobile health platform to improve and accelerate mental health diagnostics.
The INTER-PSY study, which mirrors the design of the upcoming FDA regulatory trial, will be conducted as a single-site, prospective, double-blind, within-subject comparison study (pre- registered). Data gathered from this collaboration will be pivotal in refining the final experimental parameters and optimising machine learning algorithms for BlinkLab’s FDA registrational study, specifically targeting diagnostic applications.
INTER-PSY is a large autism expertise centre in the Netherlands, offering diagnostics, guidance, and treatment for young children, adolescents, adults, and the elderly with psychological and psychiatric complaints.
“Our collaboration with INTER-PSY is one of the final steps in the prospective validation of BlinkLab’s platform before we commence our FDA registration trial later this year,” Dr. Henk-Jan Boele, CEO of BlinkLab, said,
“I’m deeply appreciative of INTER-PSY’s partnership on this critical journey. As part of the large SCANNER consortium in Europe, this study with INTER-PSY will also specifically address autism diagnosis in females.
“Our BlinkLab team is in the final phase of fine-tuning our AI models and algorithms to ensure they meet the highest standards of accuracy, safety, and efficiency. We remain fully committed to executing our strategy and delivering long-term value to all our stakeholders.”
